Burzynski Research Institute, Inc. BZYR

Company Overview

Burzynski Research Institute, Inc. (BZYR) is a privately held biomedical research organization based in the United States that focuses on experimental cancer research, particularly the investigation of antineoplastons—synthetic peptide and amino acid derivatives proposed for use in cancer treatment. The organization operates within the biotechnology and oncology research domains and has historically positioned itself as a research-focused entity rather than a commercial pharmaceutical manufacturer.

The institute was founded in the 1970s and has been closely associated with the clinical theories and research of its founder, Stanislaw R. Burzynski, MD, PhD. Over time, the organization evolved primarily as a sponsor of clinical trials rather than as a developer of FDA-approved therapies. Publicly available information indicates that BZYR does not currently generate revenue from approved pharmaceutical products, and its activities have largely centered on investigational research. Data regarding commercial success or validated clinical efficacy remains inconclusive based on available public sources.